Tibor Kovacsovics,
MD
Languages Spoken: English
Dr. Kovacsovics graduated from the University of Geneva Medical School, and was a Resident in Internal Medicine at the Clinique Médicale Thérapeutique at Geneva University Hospital, Switzerland, after which he became Chief Resident at the same institution. He also completed training as a Research Assistant at the Institute of Biochemistry at the University of Lausanne, Switzerland. He then became a Clinical and Research Fellow in Medicine, Hematology-Oncology, at Massachusetts General Hospital and Brigham and Women’s Hospital, Harvard Medical School. This was followed by positions as “Chef de Clinique” and “Médecin Associé” in the Division of Hematology at Lausanne University Hospital, Switzerland, where he set up the autologous hematopoietic stem cell transplant program. In 2004 he was recruited to the Faculty at Oregon Health Science University, where he developed a program in acute leukemia, with a focus on innovative clinical trials and molecular diagnostics. Dr. Kovacsovics has served as both principal investigator and co-investigator on numerous clinical trials and grants. Many of his clinical trials focus on new agents for treatment of acute leukemias. He is a member of multiple professional societies, and was the chairman of the Swiss Leukemia Cooperative Group (SAKK) from 2002-2004. He has published over forty peer-reviewed manuscripts, and is a regular reviewer for many top Hematology journals, including Blood, American Journal of Cancer, Haematologica, and Leukemia.
Dr. Kovacsovics brings to the University of Utah extensive expertise in the clinical management of patients with hematologic malignancies, particularly acute leukemias. In his role at the University of Utah, Dr. Kovacsovics will serve as the Medical Director for the Inpatient Service of the Division of Hematology and Hematologic Malignancies. In his role as Associate Director of Hematologic Malignancy Clinical Research in the HCI Clinical Trials Office, he will establish a phase 1 program in hematologic malignancies, coordinate clinical research in the Division and develop a Clinical-translational Research Network suitable to carry out multicenter investigator-initiated studies in hematologic malignancies, with an emphasis on correlative science. He will also develop relationships with community practices to engage community practices in HCI-based clinical trials and increase the number of patients treated on clinical trials.
Clinical Locations
Clinic 2C/BMT, Blood and Marrow Transplant
801-585-2626
Hematology Clinic
801-585-2626
Specialties
Board Certification and Academic Information
| Academic Departments | Internal Medicine
-
Professor (Clinical) |
| Academic Divisions | Hematology/BMT |
Patient Rating
The Patient Rating score is an average of all responses to care provider related questions on our nationally-recognized Press Ganey Patient Satisfaction Survey.
Responses are measured on a scale of 1 to 5 with 5 being the best score.
Likelihood of recommending care provider
4.7/ 5
Care provider spoke using clear language
4.7/ 5
Care provider's explanation of condition/problem
4.7/ 5
My confidence in care provider
4.7/ 5
Care provider's effort to include me in decisions
4.6/ 5
Wait time at clinic
3.3/ 5
Time care provider spent with me
4.5/ 5
Care provider's concern for questions & worries
4.6/ 5
Care provider's friendliness and courtesy
4.7/ 5
Patient Comments
Patient comments are gathered from our Press Ganey Patient Satisfaction Survery and displayed in their entirety. Patients are de-identified for confidentiality and patient privacy.
UofU Patient
May 13, 2019
Dr Kovascovics is the best! He is a very compassionate and caring doctor.
UofU Patient
May 07, 2019
It is all good from the lab to the PA to the physician.
UofU Patient
April 17, 2019
doctor was running late my appointment was at 9:30 he came in about 10:40 and I was anxious my next appointment was at 11 at the University which I feel I would have like more time to talk to the doctor it was a hurry up appointment I have had the experience of drive 92 miles one way and not been seen very upsetting do not want to do that again
UofU Patient
April 12, 2019
I recommended your Cancer Institute to my 3,000 Facebook friends!
UofU Patient
February 07, 2019
Waited one hour past my appointment time for a four minute discussion of my issue
UofU Patient
January 27, 2019
I absolutely feel in great hands with Dr. Kovascovics! I wouldn't go anywhere else!
UofU Patient
January 04, 2019
Dr Kovasovics and his staff are amazing! They are having a hard time trying to determine what is wrong with my blood issues, but he is determined to figure it out! I appreciate him and his staff and completely trust he will figure this out!
UofU Patient
December 21, 2018
Dr. K. is very friendly, professional and caring. We have a very good relationship.
UofU Patient
December 17, 2018
knowledgeable oncologist as well as PA. answered all of my questions and gave me contact information in case I had more.
UofU Patient
December 07, 2018
Care provider-- Dr. Kovoaovics is very knowledgeable, personable, and caring doctor. He is an outstanding care provider who I would recommend to anyone and everyone.
UofU Patient
October 18, 2018
I felt like the appointment was a waste and he was trying to brush me off to another doctor. he keeps calling me a difficult patient
UofU Patient
October 05, 2018
Dr. K is knowledgeable and I trust him totally.
UofU Patient
September 21, 2018
Dr. K and his assistant are a great combination. We look forward to coming.
UofU Patient
September 18, 2018
Dr much more friendly and seemed more caring. He probably was just having a bad day before. Sorry to have listed that. I feel so blessed to have my provider~~
UofU Patient
August 04, 2018
I am somewhat hearing impared and the P A was difficult for me to understand.
UofU Patient
August 03, 2018
I know I have an amazing, intelligent MD. I just don't always feel he cares.
UofU Patient
March 29, 2018
I appreciate these caregivers they care.
UofU Patient
March 23, 2018
Dr. K. is always very kind yet straightforward adout my condition. I have great confidence in him.
UofU Patient
September 18, 2017
I am very grateful for the care & concern he has given me. I enjoy my time with him. he has used good judgement in my care.
UofU Patient
September 14, 2017
Dr K explains my condition, treatment, and results of treatment very well. He is clearly delighted at the effectiveness of the treatment, and communicates that clearly. This is very encouraging.
UofU Patient
September 05, 2017
Felt the doctor was there to help treat my condition and not just tell me about it.
UofU Patient
September 04, 2017
Very happy and confident with Dr Kovacsovics expertise and care. My nurse practioner Mary S. is also exceptional.
UofU Patient
July 14, 2017
Everyone seemed to be doing their job well.
UofU Patient
June 21, 2017
I'm very grateful
UofU Patient
June 16, 2017
Dr. K has always been very clear in his explanations. In our meetings over a period of almost six months he always takes his time in explaining his plan, and in answering my questions and concerns. I have never felt rushed, quite the contrary, always felt that I was treated as a patient whos deserved the time needed for explanations and discussions. And in this meeting he gave me the good news that my cancer was in "complete remssion". I will of course be followed closely for some time, and the situation may change, but, for the time being, it looks like the treatment has been very successful. Thank you very much, Dr. K, for the excellent care I have received from you. I I have great confidence in your judgement and very much appreciate the style in which you have treated me.
UofU Patient
June 04, 2017
Dr. K has been very good with me in keeping me informed about the progress of my condition. He is very warm and I feel that our communication if very good.
UofU Patient
May 18, 2017
This visit was much better than the last one.
UofU Patient
March 27, 2017
Dr. K has always explained everything thoroughly and in a manner that I can understand.
UofU Patient
February 20, 2017
Dr. Kovacsovics and his staff involved in my visits were all wonderful. My condition, future treatment and questions were well addressed in terms I understood. I've never had such a level of trust as I have in Dr. Kovacsovics. He is very thorough and searched for answers until he was sure he had the right answers. There are no words to describe my level of appreciation and gratitude for him.
UofU Patient
February 17, 2017
Dr. K is great. I have confidence in his judgement in regards to my condition
UofU Patient
February 16, 2017
I have the greatest confidence in all of the medical team at Huntsman.
UofU Patient
February 10, 2017
The doctor and his staff were very caring, kind and spoke in lay terms, which I greatly appreciate.
UofU Patient
January 02, 2017
Dr Kovacsovics explained carefully my situation and the process by which he came to decisions on treatment, in particular the meetings with other specialists and the interpretation of test results. Obviously a careful diagnosis. I have great confidence in the doctor and the process.
UofU Patient
December 19, 2016
Dr K explained that more information and consultation with other specialists was needed for proper diagnosis and treatment, and arranged for the necessary follow-up. His plan seemed very reasonable, I came out feeling that I was in good hands.
UofU Patient
October 24, 2016
Always knows my case and well organized.
UofU Patient
October 05, 2016
Dr K is awesome
UofU Patient
September 30, 2016
PA was apologetic about Dr being late, but was able to provide answers to most questions, was courteous and able to address concerns. Previously, Dr K was unwilling to answer questions, stating, "too many questions!, as well as, "how many times do I have to answer these questions?" (or) on several occasions, stated "we will address that when the time comes" On initial admittance, we were told to "ask as many questions as necessary, and if you dont feel confident in the answer, ask again". We felt that we were lost in the process, toward the end, when some of our scheduled appts were apparently lost. Staff was apologetic, we felt left out.
UofU Patient
September 21, 2016
Dr. Kovascovics gave us such good service. He is very thorough, and knowledgeable. He explained things well to my NP daughter and to me in a way I could understand. His friendly, kind manner was very appreciated.
UofU Patient
September 01, 2016
Dr Kovacsovics and Mary are a great team they keep me informed of my condition and are on top of any new treatments available. They are the best.
UofU Patient
August 26, 2016
I was so frustrated by the time the physician saw me that I felt out of time to discuss my concerns adequately.
UofU Patient
August 23, 2016
No problem
UofU Patient
August 22, 2016
Very good experience, very caring and informative visit with Dr. K.
UofU Patient
July 01, 2016
Cant say more!
UofU Patient
June 26, 2016
No bad experiences. Greatly impressed with everyone and everything.
UofU Patient
April 25, 2016
All providers were excellent
UofU Patient
April 22, 2016
I know I am in the best hands around. I have full confidence in all my caregivers.
UofU Patient
April 01, 2016
My only complaint was the hour plus that I had to wait for the doctor for my follow-up appointment after the bone-marrow biopsy the previous week.
UofU Patient
March 28, 2016
excellent experience
UofU Patient
February 26, 2016
They always make me feel good, knowing that there's people there who cares I mean there like family I have a real good Dr. He is the best Dr. K
UofU Patient
December 03, 2015
We had a good experience with Dr. T. He was not in a hurry. He was relaxed and spent plenty of time to examine me and answer any questions.
UofU Patient
October 27, 2015
when I was waiting for Dr to come to see me that I had been waiting for about 40 min Dr came into.
UofU Patient
September 18, 2015
I am very happy Dr. Kovacsovics has agreed to take me as a patient and direct my care in conjunction with my hematologist-oncologist (Dr. KristieBobolis) in California, where I live.
UofU Patient
September 03, 2015
Wish there was a 6 (excellent) I press it.
UofU Patient
August 11, 2015
Dr. K was very apologetic concerning our last visit where we did not see him.... and he was on time and very informative during this visit. He also had good news to impart....
UofU Patient
July 17, 2015
impressed with the doctors
UofU Patient
July 13, 2015
Dr. K did a great job of explaining my labs and the option I had for my treatment. Great Doctor.
UofU Patient
July 04, 2015
Dr K is a very good Dr.
UofU Patient
June 22, 2015
All went very well the staf is very good and we know where we are at and what is going on
UofU Patient
May 29, 2015
We do not have contemplates at all the staff is very good
UofU Patient
May 05, 2015
My Dr is excellent. I feel like he explains things to me so I can understand. I can ask him any questions I have about treatment or meds. I trust his judgement and I feel he is on top of the treatment of Myeloma .
UofU Patient
April 19, 2015
I really like Dr. K. he listens to my wants about my treatment and offers additional help if I want it.
UofU Patient
January 16, 2015
Very, very good experience from access point, etc. I am getting tired, however, of being asked to do a survey at a minimum of once a week.
UofU Patient
November 28, 2014
I like and respect Dr. Kovacsovics, his direct manner, and straightforward manner. I appreciated his comments about re-staging my disease and the tests that would entail. I look forward to being under his care.
UofU Patient
November 04, 2014
We spent probably 20 minutes with the nurse and maybe 1 other person in the exam room before the Doctor came in. I realize he has a lot of people to see each day but he interrupted our comments often as we made statements to him that might better explain our concerns. When we are interrupted like that and that many times, it tells me he thinks his time is worth more than our time. Also, when we are coming to a place like Huntsman for the first time, everyone is not up to speed on everything discussed. In my case, I need it repeated certainly 2 or 3 times so I get the message. In this visit with this doctor, I felt I could not do that.
UofU Patient
October 12, 2014
I have never been treated with such kindness and concern anywhere else. I felt especially well cared for and understood by the doctors. They didn't make me feel like they only had 5 minutes to give me and they made sure we understood everything and was comfortable with all decisions made. This was the most respectful visit with a doctor I have ever had
UofU Patient
July 07, 2014
Dr. Nance and Dr. Kovascovics have been very informative regarding my condition. I feel at ease when they explain test results to me in a manner that I can understand. They are excellent doctors.
UofU Patient
July 06, 2014
Better than the experience at LDS hospital
UofU Patient
June 20, 2014
My bone marrow biopsy was a "pleasant" experience. Renee talked to me the entire time and made me feel at ease during the procedure.
UofU Patient
May 28, 2014
I have the utmost respect for Dr. Kovacsovics. He never seems too busy when he is examining me and any questions or concerns I have regarding my condition, Dr. Kovacsovics always attentively listens then explains things to me in terms I can understand. He is the utmost professional.
UofU Patient
May 20, 2014
I noticed that Dr Tibor J Kovacsovics was a little hurry from questions and some not understand - an inter peter had a little hard time to transferred from English to ASL so hopefully next visit and have Dr Kovacsovics be a little patience and take time.
UofU Patient
May 11, 2014
They take the time to answer all of our questions and concerns. So far the communications about treatment drugs and side-effects have been very good. That helps a lot with this chemo stuff.
UofU Patient
April 13, 2014
Was a good experience
UofU Patient
April 08, 2014
Dr. Kovacsovics was very courteous and explained my results and further care options clearly. Since the results so far are quite positive, I have good confidence in his judement and care recommendations.
UofU Patient
December 07, 2013
Great.
UofU Patient
October 07, 2013
I have already recommended the Huntsman to others. I have been to several hospitals because of my cancer and I can honestly say that this is the first hospital where I feel at home. This is also one of the only hospitals where i have not felt like I had to be my own Doctor. I trust my team and know they are keeping close watch on me. This really takes a lot of stress off my shoulders.
UofU Patient
October 05, 2013
Excellent doctor!
UofU Patient
September 25, 2013
I appreciated the cautious approach rather than just jumping into Chemo. I'm glad there will be more tests done and evaluated before a diagnosis and treatment plan will be advised.
UofU Patient
August 23, 2013
As an inpatient when I expressed concern on a certain issue to my treatment I was very impressed that they had a specialist from every possible area come talk to me about my options.
UofU Patient
April 21, 2013
good
UofU Patient
April 16, 2013
Dr K spoke to other people about choices in my treatment but I only know of the one choice that I was told, I would really like to try something less harmful to my body.
Dr. Kovacsovics graduated from the University of Geneva Medical School, and was a Resident in Internal Medicine at the Clinique Médicale Thérapeutique at Geneva University Hospital, Switzerland, after which he became Chief Resident at the same institution. He also completed training as a Research Assistant at the Institute of Biochemistry at the University of Lausanne, Switzerland. He then became a Clinical and Research Fellow in Medicine, Hematology-Oncology, at Massachusetts General Hospital and Brigham and Women’s Hospital, Harvard Medical School. This was followed by positions as “Chef de Clinique” and “Médecin Associé” in the Division of Hematology at Lausanne University Hospital, Switzerland, where he set up the autologous hematopoietic stem cell transplant program. In 2004 he was recruited to the Faculty at Oregon Health Science University, where he developed a program in acute leukemia, with a focus on innovative clinical trials and molecular diagnostics. Dr. Kovacsovics has served as both principal investigator and co-investigator on numerous clinical trials and grants. Many of his clinical trials focus on new agents for treatment of acute leukemias. He is a member of multiple professional societies, and was the chairman of the Swiss Leukemia Cooperative Group (SAKK) from 2002-2004. He has published over forty peer-reviewed manuscripts, and is a regular reviewer for many top Hematology journals, including Blood, American Journal of Cancer, Haematologica, and Leukemia.
Dr. Kovacsovics brings to the University of Utah extensive expertise in the clinical management of patients with hematologic malignancies, particularly acute leukemias. In his role at the University of Utah, Dr. Kovacsovics will serve as the Medical Director for the Inpatient Service of the Division of Hematology and Hematologic Malignancies. In his role as Associate Director of Hematologic Malignancy Clinical Research in the HCI Clinical Trials Office, he will establish a phase 1 program in hematologic malignancies, coordinate clinical research in the Division and develop a Clinical-translational Research Network suitable to carry out multicenter investigator-initiated studies in hematologic malignancies, with an emphasis on correlative science. He will also develop relationships with community practices to engage community practices in HCI-based clinical trials and increase the number of patients treated on clinical trials.
Academic Locations
Huntsman Cancer Institute
801-585-2626
Board Certification and Academic Information
| Academic Departments | Internal Medicine
-
Professor (Clinical) |
| Academic Divisions | Hematology/BMT |
Research Interests
- Acute Myeloid Leukemia (AML)
- Acute Lymphoblastic Leukemia
- Chemotherapy
- Hematopoietic Stem Cell Transplantation
Education History
| Fellowship | Brigham and Women's Hospital Clinical and Research Fellow in Medicine, Hematology-Oncology Clinical Fellow |
| Fellowship | Massachusetts General Hospital Clinical and Research Fellow in Medicine, Hematology-Oncology Clinical Fellow |
| Chief Resident | Clinique Médicale Thérapeutique, Geneva University Hospital Internal Medicine Chief Resident |
| Residency | Clinique Médicale Thérapeutique, Geneva University Hospital Internal Medicine Resident |
| Postdoctoral Fellowship | University of Lausanne Research Assistant, Institute of Biochemistry Postdoctoral Fellow |
| Professional Medical | University of Geneva Medical School Medicine M.D. |
Selected Publications - Journal Articles
Journal Article
- Fathi AT, Erba HP, Lancet JE, Stein EM, Ravandi F, Faderl S, Walter RB, Advani AS, DeAngelo DJ, Kovacsovics TJ, Jillella A, Bixby D, Levy MY, OMeara MM, Ho PA, Voellinger J, Stein AS (2018 Jul 25). A phase 1 trial of vadastuximab talirine combined with hypomethylating agents in patients with CD33 positive AML.LID - blood-2018-03-841171 [pii]LID - 10.1182/blood-2018-03-841171 [doi]. (Epub ahead of print) Blood.
- Cortes J, Perl AE, Dohner H, Kantarjian H, Martinelli G, Kovacsovics T, Rousselot P, Steffen B, Dombret H, Estey E, Strickland S, Altman JK, Baldus CD, Burnett A, Kramer A, Russell N, Shah NP, Smith CC, Wang ES, Ifrah N, Gammon G, Trone D, Lazzaretto D, Levis M (2018 Jul). Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial. Lancet Oncol, 19(7), 889-903.
- Varedi D, Kovacsovics T, Downs Kelly E, Abraham J, Cowley J, Barrell K, Revelo MP, Stehlik J, Drakos S, Marrouche N, Wilson B, Swanson EA, Fang J, Nativi-Nicolau J (2018 Jul). Unmasking Early Wild-Type Transthyretin Amyloidosis Cardiomyopathy in a Patient With Refractory Atrial Fibrillation and Unremarkable Cardiac Imaging. Circ Heart Fail, 11(7), e004812.
- Than H, Qiao Y, Huang X, Yan D, Khorashad JS, Pomicter AD, Kovacsovics TJ, Marth GT, OHare T, Deininger MW (2018 Mar 27). Ongoing clonal evolution in chronic myelomonocytic leukemia on hypomethylating agents: a computational perspective.LID - 10.1038/s41375-018-0050-z [doi]. (Epub ahead of print) Leukemia.
- Kovacsovics TJ, Mims A, Salama ME, Pantin J, Rao N, Kosak KM, Ahorukomeye P, Glenn MJ, Deininger MWN, Boucher KM, Bavisotto LM, Gutierrez-Sanchez G, Kennedy TP, Marcus SG, Shami PJ (2018 Feb 27). Combination of the low anticoagulant heparin CX-01 with chemotherapy for the treatment of acute myeloid leukemia. Blood Adv, 2(4), 381-389.
- Stein EM, Walter RB, Erba HP, Fathi AT, Advani AS, Lancet JE, Ravandi F, Kovacsovics T, DeAngelo DJ, Bixby D, Faderl S, Jillella AP, Ho PA, OMeara MM, Zhao B, Biddle-Snead C, Stein AS (2018 Jan 25). A phase 1 trial of vadastuximab talirine as monotherapy in patients with CD33-positive acute myeloid leukemia. Blood, 131(4), 387-396.
- Gordon MJ, Tardi P, Loriaux MM, Spurgeon SE, Traer E, Kovacsovics T, Mayer LD, Tyner JW (2017 Feb). CPX-351 exhibits potent and direct ex vivo cytotoxicity against AML blasts with enhanced efficacy for cells harboring the FLT3-ITD mutation. Leuk Res, 53, 39-49.
- Traer E, Martinez J, Javidi-Sharifi N, Agarwal A, Dunlap J, English I, Kovacsovics T, Tyner JW, Wong M, Druker BJ (2016 Nov 15). FGF2 from Marrow Microenvironment Promotes Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia. Cancer Res, 76(22), 6471-6482.
- Tantravahi SK, Szankasi P, Khorashad JS, Dao KH, Kovacsovics T, Kelley TW, Deininger MW (). A Phase II Study of the Efficacy, Safety and Determinants of Response to 5-Azacitidine (Vidaza®) in Patients with Chronic Myelomonocytic Leukemia. Leuk Lymphoma, DOI:10.3109/104.
- Yousef S, Marvin J, Steinbach M, Langemo A, Kovacsovics T, Binder M, Krger N, Luetkens T, Atanackovic D (). Immunomodulatory molecule PD-L1 is expressed on malignant plasma cells and myeloma-propagating pre-plasma cells in the bone marrow of multiple myeloma patients. Blood Cancer J, 5(3), doi: 10.1038/b.
- Brammer JE, Stentz A, Gajewski J, Curtin P, Hayes-Lattin B, Kovacsovics T, Leis JF, Meyers G, Nemecek E, Subbiah N, Frires R, Palmbach G, Avraham GP, Slater S, Maziarz RT (2015 Jan). Nonmyeloablative allogeneic hematopoietic stem cell transplant for the treatment of patients with hematologic malignancies using busulfan, fludarabine, and total body irradiation conditioning is effective in an elderly and infirm population. Biol Blood Marrow Transplant, 21(1), 89-96.
- Yousef S, Kovacsovics-Bankowski M, Salama ME, Bhardwaj N, Steinbach M, Langemo A, Kovacsovics T, Marvin J, Binder M, Panse J, Kroger N, Luetkens T, Atanackovic D (2015). CD229 is expressed on the surface of plasma cells carrying an aberrant phenotype and chemotherapy-resistant precursor cells in multiple myeloma. Hum Vaccin Immunother, 11(7), 1606-11.
- Cogle CR, Goldman DC, Madlambayan GJ, Leon RP, Al Masri A, Clark HA, Asbaghi SA, Tyner JW, Dunlap J, Fan G, Kovacsovics T, Liu Q, Meacham A, Hamlin KL, Hromas RA, Scott EW, Fleming WH (2014 Oct). Functional integration of acute myeloid leukemia into the vascular niche. Leukemia, 28(10), 1978-87.
- Scott EC, Heitner SB, Dibb W, Meyers G, Smith SD, Abar F, Kovacsovics T, Perez-Avraham G, Stentz A, Frires R, Dibb J, Maziarz RT (2014 Oct). Induction bortezomib in Al amyloidosis followed by high dose melphalan and autologous stem cell transplantation: a single institution retrospective study. Clin Lymphoma Myeloma Leuk, 14(5), 424-430.e1.
- Lancet JE, Cortes JE, Hogge DE, Tallman MS, Kovacsovics TJ, Damon LE, Komrokji R, Solomon SR, Kolitz JE, Cooper M, Yeager AM, Louie AC, Feldman EJ (2014 May 22). Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AML. Blood, 123(21), 3239-46.
- Lancet JE, Cortes JE, Hogge DE, Tallman MS, Kovacsovics TJ, Damon LE, Komrokji R, Solomon SR, Kolitz JE, Cooper M, Yeager AM, Louie AC, Feldman EJ (). Phase II, multicenter, randomized, open label trial of CPX-351 (cytarabine:daunorubicin) liposome injection versus cytarabine and daunorubicin in patients with untreated AML 60-75 years of age. Blood.
- Tyner JW, Yang WF, Bankhead A 3rd, Fan G, Fletcher LB, Bryant J, Glover JM, Chang BH, Spurgeon SE, Fleming WH, Kovacsovics T, Gotlib JR, Oh ST, Deininger MW, Zwaan CM, Den Boer ML, van den Heuvel-Eibrink MM, OHare T, Druker BJ, Loriaux MM (2013 Jan 1). Kinase pathway dependence in primary human leukemias determined by rapid inhibitor screening. Cancer Res, 73(1), 285-96.
- Dunlap J, Beadling C, Warrick A, Neff T, Fleming WH, Loriaux M, Heinrich MC, Kovacsovics T, Kelemen K, Leeborg N, Gatter K, Braziel RM, Press R, Corless CL, Fan G (2012 Dec). Multiplex high-throughput gene mutation analysis in acute myeloid leukemia. Hum Pathol, 43(12), 2167-76.
- Faderl S, Wetzler M, Rizzieri D, Schiller G, Jagasia M, Stuart R, Ganguly S, Avigan D, Craig M, Collins R, Maris M, Kovacsovics T, Goldberg S, Seiter K, Hari P, Greiner J, Vey N, Recher C, Ravandi F, Wang ES, Vasconcelles M, Huebner D, Kantarjian HM (2012 Jul 10). Clofarabine plus cytarabine compared with cytarabine alone in older patients with relapsed or refractory acute myelogenous leukemia: results from the CLASSIC I Trial. J Clin Oncol, 30(20), 2492-9.
- Claxton D, Erba HP, Faderl S, Arellano M, Lyons RM, Kovacsovics T, Gabrilove J, Huebner D, Gandhi PJ, Kantarjian H (2012 Mar). Outpatient consolidation treatment with clofarabine in a phase 2 study of older adult patients with previously untreated acute myelogenous leukemia. Leuk Lymphoma, 53(3), 435-40.
- Nemecek ER, Guthrie KA, Sorror ML, Wood BL, Doney KC, Hilger RA, Scott BL, Kovacsovics TJ, Maziarz RT, Woolfrey AE, Bedalov A, Sanders JE, Pagel JM, Sickle EJ, Witherspoon R, Flowers ME, Appelbaum FR, Deeg HJ (2011 Mar). Conditioning with treosulfan and fludarabine followed by allogeneic hematopoietic cell transplantation for high-risk hematologic malignancies. Biol Blood Marrow Transplant, 17(3), 341-50.
- de Witte T, Hagemeijer A, Suciu S, Belhabri A, Delforge M, Kobbe G, Selleslag D, Schouten HC, Ferrant A, Biersack H, Amadori S, Muus P, Jansen JH, Hellstrom-Lindberg E, Kovacsovics T, Wijermans P, Ossenkoppele G, Gratwohl A, Marie JP, Willemze R (2010 Oct). Value of allogeneic versus autologous stem cell transplantation and chemotherapy in patients with myelodysplastic syndromes and secondary acute myeloid leukemia. Final results of a prospective randomized European Intergroup Trial. Haematologica, 95(10), 1754-61.
- Kantarjian HM, Erba HP, Claxton D, Arellano M, Craig M, Douer D, Gabrilove J, Lyons R, Kovacsovics T, Maris M, Petersdorf S, Shami P, Yeager A, Eckert S, Abichandani R, Faderl S (). Phase II study of clofarabine monotherapy in previously untreated older adults with acute myeloid leukemia and unfavorable prognostic factors. J Clin Oncol, 28, 549.
- Frossard V, Ketterer N, Rosselet A, Meier P, Cairoli A, Duchosal MA, Kovacsovics T (2009 Jul). Early intensification and autologous stem cell transplantation in patients with systemic AL amyloidosis: a single-centre experience. ASCP CheckSample Series, 88(7), 681-5.
- Fowler CJ, Dunn A, Hayes-Lattin B, Hansen K, Hansen L, Lanier K, Nelson V, Kovacsovics T, Leis J, Calandra G, Maziarz RT (2009 Jun). Rescue from failed growth factor and/or chemotherapy HSC mobilization with G-CSF and plerixafor (AMD3100): an institutional experience. Bone Marrow Transplant, 43(12), 909-17.
- Tyner JW, Deininger MW, Loriaux MM, Chang BH, Gotlib JR, Willis SG, Erickson H, Kovacsovics T, OHare T, Heinrich MC, Druker BJ (2009 May 26). RNAi screen for rapid therapeutic target identification in leukemia patients. Proc Natl Acad Sci U S A, 106(21), 8695-700.
- Tavernier E, Boiron JM, Huguet F, Bradstock K, Vey N, Kovacsovics T, Delannoy A, Fegueux N, Fenaux P, Stamatoullas A, Tournilhac O, Buzyn A, Reman O, Charrin C, Boucheix C, Gabert J, Lheritier V, Vernant JP, Dombret H, Thomas X (2007 Sep). Outcome of treatment after first relapse in adults with acute lymphoblastic leukemia initially treated by the LALA-94 trial. Leukemia, 21(9), 1907-14.
- Buchegger F, Antonescu C, Delaloye AB, Helg C, Kovacsovics T, Kosinski M, Mach JP, Ketterer N (2006 Jun 19). Long-term complete responses after 131I-tositumomab therapy for relapsed or refractory indolent non-Hodgkin's lymphoma. Br J Cancer, 94(12), 1770-6.
- Dhedin N, Dombret H, Thomas X, Lheritier V, Boiron JM, Rigal-Huguet F, Vey N, Kuentz M, Reman O, Witz F, Delannoy A, Kovacsovics T, Bradstock K, Charrin C, Boucheix C, Gabert J, Blaise D, Fiere D, Vernant JP (2006 Feb). Autologous stem cell transplantation in adults with acute lymphoblastic leukemia in first complete remission: analysis of the LALA-85, -87 and -94 trials. Leukemia, 20(2), 336-44.
- Betticher DC Martinelli G, Radford JA, Kaufmann M, Dyer MJ, Kaiser U, Aulitzky WE, Beck J, von Rohr A, Kovacsovics T, Cogliatti SB, Cina S, Maibach R, Cerny T, Linch DC (). Sequential high dose chemotherapy as initial treatment for aggressive sub-types of non-Hodgkin lymphoma: results of the international randomized phase III trial (MISTRAL). Ann Oncol, 17, 1546.
- Vey N, Thomas X, Picard C, Kovacsovics T, Charrin C, Cayuela JM, Dombret H, Dastugue N, Huguet F, Bastard C, Stamatoulas A, Giollant M, Tournilhac C, McIntyre E, Buzyn A, Bories D, Kuentz M, Dreyfus F, Delannoy A, Raynaud S, Gratecos N, Bordessoule D, de Botton S, Preudhomme C, Reman O, Troussard X, Pigneux A, Bilhou C, Vernant JP, Gabert J (). Allogeneic stem cell transplantation improves the outcome of adults with t(1;19)/E2A-PBX1 and t(4;11)/MLL-AF4 positive B-cell acute lymphoblastic leukemia: results of the prospective multicenter LALA-94 study. Leukemia, 20, 2155.
- Antonescu C, Bischof Delaloye A, Kosinski M, Monnin P, Schaffland AO, Ketterer N, Grannavel C, Kovacsovics T, Verdun FR, Buchegger F (2005 Aug). Repeated injections of 131I-rituximab show patient-specific stable biodistribution and tissue kinetics. Eur J Nucl Med Mol Imaging, 32(8), 943-51.
- Thomas X, Boiron JM, Huguet F, Dombret H, Bradstock K, Vey N, Kovacsovics T, Delannoy A, Fegueux N, Fenaux P, Stamatoullas A, Vernant JP, Tournilhac O, Buzyn A, Reman O, Charrin C, Boucheix C, Gabert J, Lheritier V, Fiere D (2004 Oct 15). Outcome of treatment in adults with acute lymphoblastic leukemia: analysis of the LALA-94 trial. J Clin Oncol, 22(20), 4075-86.
- Beyer V, Castagne C, Muhlematter D, Parlier V, Gmur J, Hess U, Kovacsovics T, Meyer-Monard S, Tichelli A, Tobler A, Jacky E, Schanz U, Bargetzi M, Hagemeijer A, de Witte T, van Melle G, Jotterand M (2004 Jul 1). Systematic screening at diagnosis of -5/del(5)(q31), -7, or chromosome 8 aneuploidy by interphase fluorescence in situ hybridization in 110 acute myelocytic leukemia and high-risk myelodysplastic syndrome patients: concordances and discrepancies with conventional cytogenetics. Cancer Genet Cytogenet, 152(1), 29-41.
- Ghielmini M, Schmitz SF, Cogliatti SB, Pichert G, Hummerjohann J, Waltzer U, Fey MF, Betticher DC, Martinelli G, Peccatori F, Hess U, Zucca E, Stupp R, Kovacsovics T, Helg C, Lohri A, Bargetzi M, Vorobiof D, Cerny T (2004 Jun 15). Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule. Blood, 103(12), 4416-23.
- Hauert J, Fernandez-Carneado J, Michielin O, Mathieu S, Grell D, Schapira M, Spertini O, Mutter M, Tuchscherer G, Kovacsovics T (2004 Jun 7). A template-assembled synthetic protein surface mimetic of the von Willebrand factor A1 domain inhibits botrocetin-induced platelet aggregation. Chembiochem, 5(6), 856-64.
- Widmer N, Beguin A, Rochat B, Buclin T, Kovacsovics T, Duchosal MA, Leyvraz S, Rosselet A, Biollaz J, Decosterd LA (2004 Apr 25). Determination of imatinib (Gleevec) in human plasma by solid-phase extraction-liquid chromatography-ultraviolet absorbance detection. J Chromatogr B Analyt Technol Biomed Life Sci, 803(2), 285-92.
- Hauert J, Fernandez-Carneado J, Mathieu S, Grell D, Schapira M, Spertini O, Tuscherer G, Kovacsovics T (). Inhibition of botrocetin-induced platelet aggregation by a template-assembled synthetic protein (TASP) based on the structure of von Willebrand factor A1 domain. Chembiochem, 5, 856.
- Gokbuget N, Bassan R, Dekker A, Dombret H, Foa R, Ifrah N, Kovacsovics T, Labar B, Mandelli F, Meloni G, Ribera JM, Smedmyr B, Vernant JP, Walewski J, Willemze R, Hoelzer D (2004). Developing a European network for adult ALL. Hematol J, 5 Suppl 3, S46-52.
- Lowenberg B, van Putten W, Theobald M, Gmur J, Verdonck L, Sonneveld P, Fey M, Schouten H, de Greef G, Ferrant A, Kovacsovics T, Gratwohl A, Daenen S, Huijgens P, Boogaerts M (2003 Aug 21). Effect of priming with granulocyte colony-stimulating factor on the outcome of chemotherapy for acute myeloid leukemia. N Engl J Med, 349(8), 743-52.
- Keating MJ, Cazin B, Coutre S, Birhiray R, Kovacsovics T, Langer W, Leber B, Maughan T, Rai K, Tjonnfjord G, Bekradda M, Itzhaki M, Herait P (2002 Jan 1). Campath-1H treatment of T-cell prolymphocytic leukemia in patients for whom at least one prior chemotherapy regimen has failed. J Clin Oncol, 20(1), 205-13.
- Spataro V, Kovacsovics T, Bach S, Pampallona S, Schapira M, Cavalli F (2000 Nov). Acute myeloid leukemia in the elderly: results of an individualized approach in two centres. Leuk Lymphoma, 39(5-6), 521-30.
- Sonneveld P, Burnett A, Vossebeld P, Ben-Am M, Rosenkranz G, Pfister C, Verhoef G, Dekker A, Ossenkoppele G, Ferrant C, Yin L, Gratwohl A, Kovacsovics T, Vellenga E, Capdeville R, Lowenberg B (2000). Dose-finding study of valspodar (PSC 833) with daunorubicin and cytarabine to reverse multidrug resistance in elderly patients with previously untreated acute myeloid leukemia. Hematol J, 1(6), 411-21.
- Fernandez-Carneado J, Grell D, Durieux P, Hauert J, Kovacsovics T, Tuchscherer G (2000). Surface grafting onto template-assembled synthetic protein scaffolds in molecular recognition. Biopolymers, 55(6), 451-8.
- Medinger P, Tissot J-D, Nicoloso de Faveri G, Kovacsovics T, Perey L, Schenider P, Zwicky C (). Autogreffe de cellules soucjes hématopoïques périphériques dans le du traitement des hémopathies malignes. Partie I : patients. Schweiz Med Wochenschr, 130, 478.
- Hartwig JH, Kung S, Kovacsovics T, Janmey PA, Cantley LC, Stossel TP, Toker A (1996 Dec 20). D3 phosphoinositides and outside-in integrin signaling by glycoprotein IIb-IIIa mediate platelet actin assembly and filopodial extension induced by phorbol 12-myristate 13-acetate. J Biol Chem, 271(51), 32986-93.
- Kovacsovics TJ, Hartwig JH (1996 Jan 15). Thrombin-induced GPIb-IX centralization on the platelet surface requires actin assembly and myosin II activation. Blood, 87(2), 618-29.
- Toker A, Bachelot C, Chen CS, Falck JR, Hartwig JH, Cantley LC, Kovacsovics TJ (1995 Dec 8). Phosphorylation of the platelet p47 phosphoprotein is mediated by the lipid products of phosphoinositide 3-kinase. J Biol Chem, 270(49), 29525-31.
- Kovacsovics TJ, Bachelot C, Toker A, Vlahos CJ, Duckworth B, Cantley LC, Hartwig JH (1995 May 12). Phosphoinositide 3-kinase inhibition spares actin assembly in activating platelets but reverses platelet aggregation. J Biol Chem, 270(19), 11358-66.
- Ribaux C, Saguem MH, Allaz AF, Kovacsovics TJ (). Maladie de Whipple: atteinte intestinale grele a presentation sous-muqueuse. Cas anatomo-clinique. Ann Pathol, 10, 191.
- Peitsch MC, Kovacsovics TJ, Isliker H (1988 Apr 6). A rapid and efficient method for the purification of the complement subcomponents C1r and C1s in zymogen form using fast protein chromatography. J Immunol Methods, 108(1-2), 265-9.
- Peitsch MC, Kovacsovics TJ, Tschopp J, Isliker H (1987 Mar 15). Antibody-independent activation of C1. II. Evidence for two classes of nonimmune activators of the classical pathway of complement. J Immunol, 138(6), 1871-6.
- Kovacsovics TJ, Peitsch MC, Kress A, Isliker H (1987 Mar 15). Antibody-independent activation of C1. I. Differences in the mechanism of C1 activation by nonimmune activators and by immune complexes: C1r-independent activation of C1s by cardiolipin vesicles. J Immunol, 138(6), 1864-70.
- Kovacsovics T, Tschopp J, Kress A, Isliker H (1985 Oct). Antibody-independent activation of C1, the first component of complement, by cardiolipin. J Immunol, 135(4), 2695-700.
- Kovacsovics TJ, Tschopp J, Kress A, Isliker H (). Antibody-independent activation of C1, the first component of complement, by cardiolipin. J Immunol, 135, 2965.
Review
- Kovacsovics T, Maziarz RT (2006 Sep). Philadelphia chromosome-positive acute lymphoblastic leukemia: impact of imatinib treatment on remission induction and allogeneic stem cell transplantation. [Review]. Curr Oncol Rep, 8(5), 343-51.
- Gogbuket BR, Dekker A, Dombret H, Foa R, Ifrah N, Kovacsovics T, Labar B, Mandelli F, Meloni G, Ribera JM, Smedmyr B, Vernant JP, Walewski J, Willemze R, Hoelzer D (). Developing a European network for ALL. [Review]. Hematol J, 5, S46.
- Kondratyev A, Rideau A, Samii K, Matthes T, Cabrol C, Kovacsovics T, Beris P (). Pathologie moléculaire de l’anémie sidéroblastique. [Review]. Hematologie, 9, 133-144.
- Kovacsovics T (2000 Oct). [Current treatment of AL amyloidosis]. [Review]. Rev Med Suisse Romande, 120(10), 771-5.
- Kovacsovics T (). Approches actuelles du traitement de l’amyloidose AL. [Review]. Revue Medicale Suisse, 120, 771.
- Kovacsovics TJ, Delaly A (1997 Jan). Intensive treatment strategies in multiple myeloma. [Review]. Semin Hematol, 34(1 Suppl 1), 49-60.
- Kovacsovics T, Delaly A (). Intensive strategies in multiple myeloma. [Review]. Semin Hematol, 34(S3), 49.
- Delaly A, Jallut D, Kovacsovics TJ (). Epidémiologie et traitement des lymphomes non-hodgkiniens chez la personne âgée. [Review]. Revue Medicale Suisse, 54, 946.
- Kovacsovics TJ (). GM-CSF and G-CSF: bilan des etudes cliniques. [Review]. Revue Medicale Suisse, 49, 1545.
Book Chapter
- Tantravahi SK, Kovacsovics T (). Myeloma. In R. Lor Randall (Ed.), Metastatic Bone Disease: An Integrated Approach to Patient Care (pp. 89-102). New York: Springer.
Conference Proceedings
Case Report
- Juster-Switlyk K, Smith AG, Kovacsovics T, Stephens D, Glenn M, Palmer CA, Quigley EP 3rd, Kolb N (2017 Feb 7). MTHFR C677T polymorphism is associated with methotrexate-induced myelopathy risk. Neurology, 88(6), 603-604.
- Kelemen K, Kovacsovics T, Braziel R, Corless C, Beadling C, Fan G (2012 May). RAS mutations in therapy-related acute myeloid leukemia after successful treatment of acute promyelocytic leukemia. Leuk Lymphoma, 53(5), 999-1002.
- Senn L, Kovacsovics T, Tarr PE, Meylan P (2009 Feb 9). Peritoneal tuberculosis after imatinib therapy. Arch Intern Med, 169(3), 312-3.
- Gambillara E, Laffitte E, Widmer N, Decosterd LA, Duchosal MA, Kovacsovics T, Panizzon RG (2005). Severe pustular eruption associated with imatinib and voriconazole in a patient with chronic myeloid leukemia. Dermatology, 211(4), 363-5.
- Halkic N, Ksontini R, Scholl B, Blanc C, Kovacsovics T, Meylan P, Muheim C, Gillet M, Mosimann F (2004 Jan). Recurrent cytomegalovirus disease, visceral leishmaniosis, and Legionella pneumonia after liver transplantation: a case report. Can J Anaesth, 51(1), 84-7.
- Ribaux C, Saguem MH, Allaz AF, Kovacsovics T (1990). [Whipple's disease. Involvement of the small intestine with submucosal presentation]. Ann Pathol, 10(3), 191-3.
Letter
- Yousef S, Marvin J, Steinbach M, Langemo A, Kovacsovics T, Binder M, Kroger N, Luetkens T, Atanackovic D (2015). Immunomodulatory molecule PD-L1 is expressed on malignant plasma cells and myeloma-propagating pre-plasma cells in the bone marrow of multiple myeloma patients [Letter to the editor]. Blood Cancer J, 5, e285.
- Tyner JW, Loriaux MM, Erickson H, Eide CA, Deininger J, MacPartlin M, Willis SG, Lange T, Druker BJ, Kovacsovics T, Maziarz R, Gattermann N, Deininger MW (2009 Feb). High-throughput mutational screen of the tyrosine kinome in chronic myelomonocytic leukemia [Letter to the editor]. Leukemia, 23(2), 406-9.
- Lovey PY, Darbellay R, Cabrol C, Roux E, Starobinski M, Helg C, Kovacsovics T, Chapuis B (1999 Oct). BCR-negative chronic myeloid leukemia in relapse after bone marrow transplantation is susceptible to remission induction by donor lymphocyte infusions [Letter to the editor]. Eur J Haematol, 63(4), 280-1.
Abstract
- Stock W, Douer D, DeAngelo DJ, Arellano M, Advani A, Damon L, Kovacsovics T, Litzow M, Rytting M, Borthakur G, Bleyer A (). Prevention and management of asparaginase/pegasparaginase-associated toxicities in adults and older adolescents; recommendations of an expert panel [Abstract]. Leuk Lymphoma, 52(12), 2237-53.
- Lancet JE, Cortes JE, Hogge DE, Tallman M, Kovacsovics T, Damon LE, Ritchie E, Komrokji RS, Louie AC, Feldman EJ (). Phase 2B Randomized Study of CPX-351 Vs. Cytarabine (CYT) + Daunorubicin (DNR) (7+3 Regimen) In Newly Diagnosed AML Patients Aged 60–75. Presented at the 52nd meeting of the American Society of Hematology [Abstract]. Blood, 116, 655.
- Tyner JW, Spurgeon S, Fletcher LB, Yang W, Kovacsovics T, Druker BJ, Loriaux MM (). A Small-Molecule Inhibitor Screen Rapidly Identifies Therapeutic Targets and Individualized Therapeutic Strategies In Patients with Acute and Chronic Leukemias. Presented at the 52nd meeting of the American Society of Hematology [Abstract]. Blood, 116, 2054.
- Gabrilove J, Faderl S, Erba HP, Claxton DF, Arellano M, Lyons RM, Kovacsovics TJ, Eckert S, Huebner D, M Kantarjian H (). Complete Response to Clofarabine Is Durable and Correlates with Survival in Previously Untreated Older Adult Patients with Acute Myeloid Leukemia (AML) and Unfavorable Prognostic Factors. Presented at the 51th meeting of the American Society of Hematology [Abstract]. Blood, 114, 2061.
- Erba HP, Faderl S, Claxton DF, Arellano M, Lyons RM, Kovacsovics TJ, Gabrilove J, Eckert S, Huebner D, Kantarjian HM (). Single-Agent Clofarabine Produces Durable Remissions in Patients with Acute Myelogenous Leukemia (AML) Who Are 70, Have Intermediate or Unfavorable Cytogenetics, Antecedent Hematological Disorders (AHD), or 2 or More Unfavorable Prognostic Factors. Presented at the 51th meeting of the American Society of Hematology [Abstract]. Blood, 114, 2083.
- Nemecek ER, Sorror ML, Doney KC, Scott BL, Kovacsovics TJ, Maziarz RT, Woolfrey AE, Sanders J, ODonnell PV, Guthrie K, Deeg HJ (). A Regimen of Treosulfan and Fludarabine Followed by Allogeneic Hematopoietic Cell Transplantation (HCT) for High-Risk Hematologic Malignancies Is Associated with Low Treatment-Related Mortality. Presented at the 50th meeting of the American Society of Hematology [Abstract]. Blood, 112, 2994.
- Rebecca B Klisovic, Steven Coutre, Tibor J Kovacsovics, Hagop M Kantarjiam, Guido J Tricot, Jeffrey W Strovel, Thomas Genna, David K Bol, Michael Hamilton, and Beverly S Mitchell (). Clinical-Biomarker Correlations in Adult AML Patients in a Phase I Trial of AVN944 Support Observations of Clinical Effect and Provide Hypotheses for Patient Selection Criteria for Further Clinical Trial. Presented at the 49th meeting of the American Society of Hematology [Abstract]. Blood, 110, 897.
- Tibor Kovacsovics, Byung Park, Brandon Hayes-Lattin, Jose F Leis, Peter T Curtin, Gabrielle Meyers, Elliot Epner, Richard T Maziarz (). Applying the Hematopoietic Cell Transplantation-Comorbidity Index (HCT-CI) in Myeloablative MUD Transplants Predicts NRM and OS Using a Modified 2-Tier Scoring System. Presented at the 49th meeting of the American Society of Hematology [Abstract]. Blood, 110, 1988.
- Erba HP, Kantarjian H, Claxton DP, Arellano M, Lyons RP, Kovacsovics TJ, Gabrilove J, Eckert S, Abichandani R, Faderl S (). Phase II Study of Single Agent Clofarabine in Previously Untreated Older Adult Patients with Acute Myelogenous Leukemia (AML) Unlikely to Benefit from Standard Induction Chemotherapy. Presented at the 50th meeting of the American Society of Hematology [Abstract]. Blood, 112, 558.
- Leis JF, Hansen KS, Curtin PT, Hayes-Lattin BM, Lanier KS, Stanton NR, Callaway CD, Fowler CJ, Dunn AM, Gruenberg D, Mauro MJ, Segal GM, Hansen LK, Menashe JI, Kovacsovics T, Simic A, and Maziarz RT (). Prognostic Models for Predicting Outcomes after Autologous Stem Cell Transplantation (ASCT) in Patients with Relapsed or Refractory Hodgkin’s Disease: How Predictive Are They? Presented at the 48th meeting of the American Society of Hematology, San Diego [Abstract]. Blood, 106, 5227.
- De Witte TM Hagemeijer A Suciu, S, Belhabri A, Delforge, M, Aul C, Aivado M, Selleslag D, Schouten H, Ferrant A, Biersack H, Amadori S, Muus P, Jehn U, Beeldens F, Jansen, J, Hellstrom-Lindberg E, Kovacsovics T, Hess U, Wijermans P, Ossenkoppele G, Gratwohl A, Marie JP, Willemze R (). Allogeneic (Allo-) or Autologous (Auto-) Peripheral Blood Stem Cell Transplantation (SCT) Randomized Versus a Second Intensive Consolidation after a Common Induction and Consolidation Course in Patients with Bad Prognosis Myelodysplastic Syndromes and Acute Myelogenous Leukemia Following MDS of More Than 6 Months Duration: The Final Analysis of a Joint Study (CRIANT) of the EORTC, EBMT, SAKK, HOVON and GIMEMA Leukemia Groups. Presented at the 48th meeting of the American Society of Hematology, San Diego [Abstract]. Blood, 106, 794.
- De Witte TM, Hagemeijer A, Suciu S, Belhabri A, Delforge MD, Aul C, Avaido M, Selleslag D, Schouten H, Biersack H, A Ferrant, Kovacsovics T, Muus P, Jansen J, Beeldens F, Gratwohl A, Hess U, Helstrm-Lindberg E, Wijermans P, Ossenkoppele GJ, Marie J-P, Willemze R, Amadori S (). The impact of post-remission therapy on outcome of patients with poor-risk MDS and secondary AML treated with intensive chemotherapy with or without stem cell transplantation in a joint study (CRIANT) of the EORTC, EBMT, SAKK, HOVON, Scandinavian and the GIMEMA leukemia groups. Presented at the 30th meeting of the European Group for Bone Marrow Transplantation, Barcelona [Abstract]. Bone Marrow Transplant, 33, S2.
- De Witte TM, Hagemeijer A, Suciu S, Belhabri A, Delforge MD, Aul C, Avaido M, Selleslag D, Schouten H, Biersack H, A Ferrant, Kovacsovics T, Muus P, Jansen J, Beeldens F, Gratwohl A, Hess U, Helstrm-Lindberg E, Wijermans P, Ossenkoppele GJ, Marie J-P, Willemze R, Amadori S (). The impact of post-remission therapy on outcome of patients with poor-risk MDS and secondary AML treated with intensive chemotherapy with or without stem cell transplantation in a joint study (CRIANT) of the EORTC, EBMT, SAKK, HOVON, Scandinavian and the GIMEMA leukemia groups. Presented at the 45th meeting of the American Society of Hematology, San Diego [Abstract]. Blood, 102, 185A.
- Sonneveld P, van der Holt B, Burnett AK, Vossebeld P, Prins A, Covelli A, Rosenkranz G, Malkhandi J, Verhoef GEG, Dekker AW, Ossenkoppele GJ, Ferrant A, Yin L, Grathwohl A, Kovacsovics T, Vellenga E, van Putten WLJ, Wheatley K, Lwenberg B (). An open label randomized controlled study in elderly patients with previously untreated acute myelogenous leukemia (AML), comparing treatment groups randomized to receive daunorubicin and cytarabine or daunorubicin, cytarabine and the MDR1 reversal agent PSC 833. Presented Presented at the 45th meeting of the American Society of Hematology, San Diego [Abstract]. Blood, 102, 185A.
- Hauert J, Fernandez J, Mathieu S, Grell D, Spertini O, Schapira M, Tuchscherer G, Kovacsovics T (). Inhibition of botrocetin-induced platelet aggregation by a template-assembled synthetic protein (TASP) based on the structure of the von Willebrand factor A1 domain. Presented at the 70th meeting of the Swiss Society of Hematology, Geneva [Abstract].
- Ghielmini M, Hsu Schmitz SF, Cogliatti, Pichert G, Fey M, Betticher D, Martinelli G, Peccatori F, Hess U, Stahel R, Zucca E, Stupp R, Kovacsovics T, Helg C, Lohri A, Bargetzi M, Vorobiof D, Cerny T (). Prolonged treatment with Rituximab significantly improves event-free survival and duration of response in patients with follicular lymphoma : a randomized SAKK trial. Presented at the 44th meeting of the American Society of Hematology, Philadelphia [Abstract]. Blood, 100, 161a.
- Meier P, Bakr M, Frossard V, Rossselet A, Kovacsovics T, Burnier M (). Renal outcome in dose-intensive therapy and autologous stem cell transplantation for AL amyloidosis. Presented at the 35th meeting of the American Society of Nephrology, Philadelphia [Abstract]. J Am Soc Nephr, 13S, 669A.
- Thomas X, Boiron JM, Huguet F, Dombret H, Bradstock K, Vey N, Kovacsovics T, Delannoy A, Fegueux N, de Botton S, Stamatoullas A, Vernant JP, Tournilhiac O, Buzyn A, Reman O, Charrin C, Boucheix C, Gabert J, Lhritier V, Fire D (). Intensive Therapy in 922 Adult Patients with Acute Lymphoblastic Leukemia (ALL): Analysis of the French-Belgian-Swiss-Australian LALA-94 trial. Presented at the 44th meeting of the American Society of Hematology, Philadelphia [Abstract]. Blood, 100, 157a.
- Ghielmini M, Hsu Schmitz SF, Cogliatti, Pichert G, Fey M, Betticher D, Martinelli G, Peccatori F, Hess U, Stahel R, Zucca E, Stupp R, Kovacsovics T, Helg C, Lohri A, Bargetzi M, Vorobiof D, Cerny T (). Maintenance treatment with 2-monthly Rituximab after standard weekly x4 Rituximab induction significantly improves event-free survival in patients with follicular lymphoma. Presented at the 8th International Conference on Lymphoma, Lugano, Switzerland [Abstract]. Ann Oncol, 13(38a), Suppl 2.
- Bakr M, Frossard V, Delabays A, Meier P, Rosselet, Tissot JD, Schapira M, Kovacsovics T (). Bakr M, Frossard V, Delabays A, Meier P, Rosselet, Tissot JD, Schapira M, Kovacsovics T. High-dose Melphalan therapy in AL amyloidosis : toxicity and response data in 8 cases. Presented at the 7th meeting of the European Society of Hematology, Florence [Abstract]. Hematology J, 3(0106), Suppl 1.
- Bakr M, Ketterer N, Rosselet A, Kovacsovics T, Frossard V, Stupp R, Bauer J, Delacrtaz F, Leyvraz S (). High dose chemotherapy and autologous blood stem cell support in patients with aggressive T-cell lymphomas. Presented at the 38th meeting of the American Society of Clinical Oncology, San Francisco [Abstract]. J Clin Oncol, 21, 287a.
- Kostakoglu L, Goldsmnith SJ, Buchegger F, Leonard JP, Illidge T, Ketterer N, Kovacsovics T, Valente N, Bischof-Delaloye (). Preliminary results of a multicenter dosimetry, efficacy and safety study with iodine-131 tositumomab in treatment of non-Hodgkin’s lymphoma (NHL). Presented at the Annual Meeting of the European Association of Nuclear Medicine, Napoli [Abstract]. European Journal of Nuclear Medicine, 28, OS73 Suppl.
- Hauert J, Fernandez J, Mathieu S, Grell D, Spertini O, Schapira M, Tuchscherer G, Kovacsovics T (). Design and synthesis of vWF TASP, a novel synthetic peptide mimicking the A1 domain of the von Willebrand factor. Presented at the 43rd meeting of the American Society of Hematology, Orlando [Abstract]. Blood, 98, 516a.
- Antonescu A, Buchegger F, Kosinsnki M, Ketterer N, Kovacsovics T, Helg C, Bischof-Delaloye (). Radioimmunotherapy (RIT) of non-Hodgkin’s lymphoma (NHL) with I-131 monoclonal antibody (Bexxar ™). Preliminary results. Presented at the Annual Meeting of the European Association of Nuclear Medicine, Napoli [Abstract]. European Journal of Nuclear Medicine, 28, OS77 Suppl.
- Hauert J, Fernandez J, Mathieu S, Grell D, Spertini O, Schapira M, Tuchscherer G, Kovacsovics T (). Design and activity of vWF-TASP, a novel synthetic molecule mimicking the A1 domain of von Willebrand factor. Presented at the XVIIIth meeting of the International Society of Thrombosis and Haemostasis, Paris [Abstract]. Thromb Haemost, 85, P2686 Suppl.
- Medinger P, Tissot JD, Nicoloso de Faveri G, Kovacsovics TJ, Perey L, Schneider P, Zwicky C (2000 Apr 1). [Autologous transplantation of peripheral blood hematopoietic stem cells in the treatment of hematological malignancies. I: patients] [Abstract]. ASCP CheckSample Series, 130(13), 478-84.
- Kovacsovics TJ, Mathieu S, Hauert J, Schapira M (). Functional characterization of the signaling pathway linking GPIb-IX engagement to actin assembly. Presented at the 42nd meeting of the American Society of Hematology, San Francisco [Abstract]. Blood, 96, 622a.
- Kovacsovics TJ, Rosselet A, Spertini O, Duchosal M, Zwicky C, Schapira M (). High-dose therapy followed by peripheral blood stem cell (PBSC) transplantation for hematological malignancies can safely be administered to selected patients up to the age of 70. Presented at the 41st meeting of the American Society of Hematology, New Orleans [Abstract]. Blood, 94, 401b.
- Donnet-Descartes V, Kovacsovics T, Wasserfallen JB (). Hospital costs of intensive chemotherapy followed by peripheral stem cell reinfusion. Presented at the 20th meeting of the European Group for Bone Marrow Transplantation, Courmayeur [Abstract]. Bone Marrow Transplant, 22, S107.
- Kovacsovics T, Lascombes F, Harvey E, Oberling F, Wesly O, Schubach W, Littlewood T, Hastings C, Rios M, Corbett R, Pui CH, Dunlop D, Reaman G, Sullivan M, Coiffier B, Kasper M, Lederlin P (). Prevention and treatment of hyperuricemia related to tumor lysis syndrome by recombinant urate oxidase SR 29142. Presented at the 30th meeting of the International Society of Pediatric Oncology, Yokohama, Japan [Abstract].
- Sonneveld, P Lowenberg B, Vossebeld J, Malkhandi J, Covelli A, Dekker AW, Ossenkepele G, Milligan D, Verhoef D, Ferrant A, Yin J, Gratwohl A, Kovacsovics T, Burnett A (). Dose-finding study of PSC833, a novel MDR reversing agent, with daunorubicin and ARA-C in untreated elderly patients with acute myeloid leukemia (AML). Presented at the 39th meeting of the American Society of Hematology, San Diego [Abstract]. Blood, 90, 566a.
- Spataro V, Delacretaz F, Schmidt PM, Cometta A, Kovacsovics T (). Intensive treatment of AML in the elderly: influence of trilineage myelodysplasia and of preexisting myelodysplastic syndrome on clinical outcome. Presented at the 38th meeting of the American Society of Hematology, Orlando, Florida [Abstract]. Blood, 88, 559a.
- Beris P, Darbellay R, Samii K, Kovacsovics TJ (). Chronic hemolytic anemia/thalassemia intermedia phenotype in a Swiss family is due to a deletion of 2 bp in exon 3 of the b-globin gene (CDs 131-132 GA). Presented at the 37th meeting of the American Society of Hematology, Seattle, Washington [Abstract]. Blood, 86, 642a.
- Kovacsovics TJ (). GPIb-IX cytoskeletal interactions: platelet involvement in platelet retraction processes. Presented at the symposium on Bernard-Soulier syndrome: GPIb-IX-V complexes in health and disease, Paris, France [Abstract].
- Kovacsovics TJ, Toker A, Bachelot C, Cantley LC, Hartwig JH (). Phosphatidylinositol 3-kinase inhibition during platelet activation by the thrombin-receptor activating peptide prevents sustained exposure of GPII-IIIa and irreversible agggregation, but not actin assembly or secretion. Presented at the 29th Meeting of the European Society of Clinical Investigation, Cambridge, UK [Abstract]. Eur J Clin Invest, 25, A42.
- Kovacsovics TJ, Hartwig JH, Cantley LC, Toker A (). Irreversible platelet aggregation and prolonged pleckstrin phosphorylation are mediated by the lipid products of phosphatidylinositol 3-kinase. Presented at the 37th meeting of the American Society of Hematology, Seattle, Washington [Abstract]. Blood, 86, 613a.
- Kovacsovics TJ, Bachelot C, Cantley LC, Hartwig JH (). Phosphatidylinositol 3-kinase inhibition during platelet activation by the thrombin-receptor activating peptide prevents sustained exposure of GPII-IIIa and irreversible agggregation, but not actin assembly. Presented at the 36th meeting of the American Society of Hematology, Nashville, Tennessee [Abstract]. Blood, 84, 533a.
- Kovacsovics TJ, Winokur R, Hartwig JH (). Preventing actin remodelling preserves platelet function during cold storage. Presented at the 35th meeting of the American Society of Hematology, St. Louis, Missouri [Abstract]. Blood, 82, 336a.
- Kovacsovics TJ, Hartwig JH (). GPIb-IX rearrangements during platelet activation provide for vWF contraction. Presented at the 35th meeting of the American Society of Hematology, St. Louis, Missouri [Abstract]. Blood, 82, 449a.
- Kovacsovics TJ, Peitsch MC, Tschopp J, Isliker H (). Antibody-independent activation of the first component of complement (C1) does not require the subcomponent C1r. Presented at the USGEB (Swiss Union of Societies for Experimental Medicine) [Abstract]. Experientia, 42, 669.
- Peitsch MC, Kovacsovics TJ, Tschopp J, Isliker H (). Antibody-independent activation of C1. II. Two classes of nonimmune activators can be distinguished. Presented at the 1st European Workshop n Complement in Human Diseases, Veszprem, Hungary [Abstract]. Complement, 3, 210.
- Kovacsovics TJ, Peitsch MC, Tschopp J, Isliker H (). Antibody-independent activation of C1. I. Differences in the mechanismof C1 activation by nonimmune activators and by immune complexes [Abstract]. Complement, 3, 202.
- Kovacsovics TJ, Kress A, Tschopp J, Isliker H (). Control by C1-INH of antibody-independent activation is modulated by a C1q-dependent C1s2 binding to the activator. Presented at the 5th Complement Workshop, Miami, Florida [Abstract]. Complement, 2, 46.
- Kovacsovics TJ, Tschopp J, Isliker H (). Antibody-independent activation of C1, the first component of complement, by cardiolipin. Presented at the 6th European Immunology Meeting, Interlaken, Switzerland [Abstract].
- Kovacsovics TJ, Tschopp J, Isliker H (). Antibody-independent activation of C1, the first component of complement, by cardiolipin. Presented at the 1st Workshop on C1, Mainz, Germany [Abstract].
- Kovacsovics TJ, Tschopp J, Isliker H (). Antibody-independent activation of C1, the first component of complement, by cardiolipin. Presented at the USGEB (Swiss Union of Societies for Experimental Medicine) [Abstract]. Experientia, 40, 609.
Global Impact
Education History
| Chief Resident | Clinique Médicale Thérapeutique, Geneva University Hospital Internal Medicine Chief Resident |
| Residency | Clinique Médicale Thérapeutique, Geneva University Hospital Internal Medicine Resident |
| Postdoctoral Fellowship | University of Lausanne Research Assistant, Institute of Biochemistry Postdoctoral Fellow |
| Professional Medical | University of Geneva Medical School Medicine M.D. |